LUCIUS Pharmaceutical announces the approval LuciRevu in Laos

Vientiane, Laos - November 11, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciRevu (Revumenib) have been approved by the Ministry of Health of Laos.

Acute myeloid leukemia with a susceptible NPM1 mutation: NPM1 mutations occur in approximately 30% of adults with AML and are associated with disease relapse and poor prognosis. Earlier World Health Organization (WHO) classification schema recognized NPM1-mutated AMLs as a unique subtype of AML, while the latest WHO and International Consensus Classification (ICC) now consider NPM1 mutations as AML-defining, albeit at different blast count thresholds. NPM1 mutational load correlates closely with disease status, particularly in the post-therapy setting, and therefore high sensitivity-based methods for detection of the mutant allele have proven useful for minimal/measurable residual disease (MRD) monitoring. MRD status has been conventionally measured by either multiparameter flow cytometry (MFC) and/or molecular diagnostic techniques, although recent data suggest that MFC data may be potentially more challenging to interpret in this AML subtype. Of note, MRD status does not predict patient outcome in all cases, and therefore a deeper understanding of the biological significance of MRD may be required. Recent studies have confirmed that NPM1-mutated cells rely on overexpression of HOX/MEIS1, which is dependent on the presence of the aberrant cytoplasmic localization of mutant NPM1 protein (NPM1c); this biology may explain the promising response to novel agents, including menin inhibitors and second-generation XPO1 inhibitors.